CLAIMS

1. An LNA antisense oligomer conjugate, comprising a single stranded LNA antisense oligomer of 8 – 26 nucleosides in length covalently bound to a conjugate moiety which comprises a galactose cluster with an asialoglycoprotein receptor targeting moiety selected from the group consisting of galactose, galactosamine, N-formyl-galactosamine, N-acetylgalactosamine, N-propionyl-galactosamine, N-n-butanoyl-galactosamine, and N-isobutanoylgalactose-amine.
2. The LNA antisense oligomer conjugate according to claim 1, wherein the galactose cluster contains two or three N-acetylgalactosamines attached to a dilysine branch point through the C-I carbons of the N-acetylgalactosamines and the N-acetylgalactosamines is linked to the branch point via linkers or spacers.
3. The LNA antisense oligomer conjugate according to claim 2, wherein the spacer is a PEG spacer.
4. The LNA antisense conjugate according to any one of claim 1 - 3, wherein the galactose cluster further comprises a pharmacokinetic modulator selected from the group consisting of C8 – C36 saturated or un-saturated fatty acid, sterol, cholesterol, palmitoyl, hexadec-8-enoyl, oleyl, (9E, 12E)-octadeca-9,12-dienoyl, dioctanoyl, and C16-C20 acyl.
5. The LNA antisense oligomer conjugate according to claim 4, wherein the pharmacokinetic modulator is attached to the galactose cluster via a linker, such as a physiologically cleavable linker.
6. The LNA antisense oligomer conjugate according to any one of claims 1 – 5, wherein the galactose cluster is covalently linked to the oligomer via a physiologically cleavable linker.
7. The LNA antisense oligomer conjugate according to claim 6, wherein the physiologically cleavable linker is selected from the group consisting of, an acid labile linker, a disulphide linker, and a region of phosphodiester linked nucleosides.
8. The LNA antisense oligomer conjugate of any one of claim 1 - 7, wherein the oligonucleotide has 8 – 18 contiguous nucleosides.